KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Change in Receivables (2016 - 2025)

Abbott Laboratories' Change in Receivables history spans 17 years, with the latest figure at -$222.0 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 240.51% year-over-year to -$222.0 million; the TTM value through Dec 2025 reached $652.0 million, down 5.64%, while the annual FY2025 figure was $652.0 million, 5.64% down from the prior year.
  • Change in Receivables for Q4 2025 was -$222.0 million at Abbott Laboratories, down from $202.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $751.0 million in Q1 2022 and bottomed at -$530.0 million in Q3 2022.
  • The 5-year median for Change in Receivables is $173.0 million (2022), against an average of $107.5 million.
  • The largest YoY upside for Change in Receivables was 637.14% in 2022 against a maximum downside of 280.42% in 2022.
  • A 5-year view of Change in Receivables shows it stood at $189.0 million in 2021, then plummeted by 280.42% to -$341.0 million in 2022, then skyrocketed by 80.06% to -$68.0 million in 2023, then soared by 332.35% to $158.0 million in 2024, then plummeted by 240.51% to -$222.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Change in Receivables are -$222.0 million (Q4 2025), $202.0 million (Q3 2025), and $410.0 million (Q2 2025).